Skip to content


Collaborating with investors who share our vision and passion

Welcome to EpiEndo Pharmaceuticals’ Investor Page. We are a clinical-stage biopharmaceutical company focused on developing innovative therapies for chronic inflammatory diseases caused by epithelial dysfunction.

Based on over 20 years of research into macrolides and their effects on the lung epithelium, our mission today is to transform the lives of patients in need by enhancing the epithelium with our unique approach to treatment.


Our shareholders share our commitment to transforming the lives of patients with chronic inflammatory diseases caused by epithelial dysfunction

EpiEndo is a privately held company with a shareholder base which includes:

  • Idunn Fund slhf

    VC fund

  • Flerie Invest AB

    VC fund

  • The EIC Fund

    EU fund

  • ABC Venture

    PE fund

  • Tunga ehf. (Iceland)

    Family office

  • Fridrik Gardarsson


Investment Opportunities

We are always open to new investment partners. If you are interested in supporting innovative drug development and the potential positive impact for millions of patients globally.

Get in touch

Investment case

  • Lead program EP395 already in Ph2a development

  • Addressing COPD, the third leading cause of death globally

  • Current global economic burden of COPD is estimated to be USD $4.8 trillion annually by 2030

  • Unique Barriolide concept is a differentiated approach to treating the causes of inflammation and disease

  • Large and growing market opportunity estimated to be USD $30 billion by 2030

  • Clear regulatory pathway

  • Experienced and dedicated leadership team with track record of delivery

OUR corporate factsheet pdf